Aug 2026
MLN4924 suppresses pancreatic cancer progression and enhances chemosensitivity to gemcitabine by targeting the PTGS2/EGFR-PI3K/Akt/mTOR signaling axis.
Results demonstrate that MLN4924 exerts antitumor effects in pancreatic cancer by targeting the PTGS2-EGFR-PI3K/AKT/mTOR axis, providing a mechanistic rationale for its clinical application in pancreatic cancer therapy.
Min Wang, Y. Mou, Jiajie Qiu et al.
· Anti-Cancer Drugs · 0 citations